Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

FDA for the treatment of Huntington's disease.
  • Reported positive clinical data from its Phase 1 clinical trial of OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), an important regulator of the lectin pathway of the immune system. A Phase 2 clinical program to evaluate OMS721 in the treatment of thrombotic microangiopathies (TMAs), a family of disorders that occurs in the microcirculation of the body's organs, most commonly the kidney and brain, is expected to begin enrollment in early 2014.
  • Announced that its proprietary Cellular Redistribution Assay technology had "unlocked" six additional Class A orphan G protein-coupled receptors (GPCRs) for drug development, bringing the total number of Class A orphan GPCRs "unlocked" by Omeros to 52. These six orphan GPCRs are linked to a series of important indications, including cardiovascular indications, certain types of cancer and Grave's disease. Omeros also announced that it had identified small molecules that interact with two non-orphan Class B GPCRs, the glucagon-like peptide 1 receptor (GLP-1R) and the parathyroid hormone 1 receptor (PTH-1R). Both of these receptors are established drug targets – GLP-1R for diabetes and PTH-1R for osteoporosis.
  • Financial ResultsTotal operating expenses for the quarter ended September 30, 2013 were $13.6 million and included non-cash expenses of $3.2 million related to rent expense and stock-based compensation. For the same period in 2012, total operating expenses were $14.5 million, which included non-cash rent and stock-based compensation expenses of $576,000.

    The decrease in total operating expenses for the quarter ended September 30, 2013 compared to the prior year quarter is primarily due to a litigation settlement expense of $3.95 million recorded in the same period in 2012, which was reimbursed by CCIC in the fourth quarter of 2012. For the quarter ended Septemb
    '/>"/>

    SOURCE Omeros Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
    2. Omeros to Present at the 12th Annual Needham Healthcare Conference
    3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
    4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
    5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
    6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
    7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
    8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
    9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
    10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
    11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2014)... , Sept. 1, 2014 Reportlinker.com announces ... in its catalogue: India Solid Waste ... http://www.reportlinker.com/p02350445/India-Solid-Waste-Management-Vehicles-Market-Forecast-and-Opportunities-2019.html In ... the main governing bodies responsible for complete handling ... On an average, around 135,000 MT solid waste ...
    (Date:9/1/2014)... The global oligonucleotide synthesis market is expected ... million in 2014, growing at a CAGR of ... synthesis market is categorized on the basis of ... The synthesized oligonucleotides segment is expected to register ... market during the forecast period, owing to an ...
    (Date:9/1/2014)... (PRWEB) September 01, 2014 The ... and Diagnostics report provides comprehensive understanding and unprecedented ... entered into by the worlds leading life science ... and analysis of how and why companies enter ... a prospective partner’s negotiated deals terms provides critical ...
    (Date:8/31/2014)... 31, 2014 Wockhardt Limited today announces a ... Anti-Infective research when two of its drugs, WCK 771 ... Product (QIDP) status from U.S. Food & Drug Administration ... against pathogens which have a high degree of unmet ... for Disease Control (a top U.S. government health and ...
    Breaking Biology Technology:India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 2India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 3India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 4India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 5India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 6India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 7India Solid Waste Management Vehicles Market Forecast and Opportunities, 2019 89.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 29.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 39.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 49.8% CAGR for Oligonucleotide Synthesis Market Globally to 2019 Says a New Research Report Available at RnRMarketResearch.com 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics Industry Analysis, Size, Share, Growth, Trends And Forecast Research Report by Researchmoz.us 4U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 2U.S. FDA Grants QIDP Status for Wockhardt Anti-Infective Drug Discovery Program 3
    ... 2008 Diffusion,Pharmaceuticals LLC, a clinical-stage drug-development ... action that enhances,oxygen diffusion, today announced that ... entitled "Bipolar Trans Carotenoid Salts and Their ... of first-in-class new chemical entities,known as trans ...
    ... Mass., April 8, 2008 Caliper Life,Sciences, Inc. (Nasdaq: ... Meeting,of Stockholders will be held on June 3, 2008, ... 68 Elm Street, Hopkinton, Massachusetts. The record,date for Caliper ... 16,2008., About Caliper Life Sciences, Caliper Life ...
    ... pain reliever lands its first national retail drug ... ... ALCiS Health, Inc., a,provider of patented pain relief products, today announced ... cream, ALCiS Daily Relief, at all of its 6,237 stores.,Its introduction onto ...
    Cached Biology Technology:Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules 2ALCiS(R) Daily Relief Now Available at Walgreens 2
    (Date:9/1/2014)... An increasing amount of research shows an association between ... sedentary lifestyle. Now, a new Cornell University study points ... programs might lead people to eat twice as much ... an action movie while snacking your mouth will see ... on the new article just published in the ...
    (Date:9/1/2014)... has improved steadily in recent yearsspurred in large part ... poor and disparities continue to widen among socioeconomic and ... School of Public Health (HSPH). , "The study provides ... efforts by many groups and individuals to improve U.S. ... indicates that these efforts need to be expanded," said ...
    (Date:9/1/2014)... The quality of the U.S. diet showed some modest ... of a reduction in the consumption of unhealthy trans ... between the rich and the poor. , , An ... and some cancers. Eating a healthy diet is an ... outcomes. Evaluating population trends in diet quality is important ...
    Breaking Biology News(10 mins):Can action movies make you fat? 2Quality of US diet shows modest improvement, but overall remains poor 2Quality of US diet shows modest improvement, but overall remains poor 3Quality of US diet improves, gap widens for quality between rich and poor 2Quality of US diet improves, gap widens for quality between rich and poor 3
    ... a Global Information System will provide valuable information for ... Institute of Environmental Health Sciences (NIEHS), one of the ... the most up-to-date data to public health and safety ... maps, as well as demographic information for local populations. ...
    ... Some 12.3 percent of all babies -- 499,008 infants -- ... according to the report released by the National Center for ... 480,000 babies) in 2002 -- and an increase of more ... in 1981. The prematurity rate was 9.4 in 1981; it ...
    ... the world's vaccine manufacturers will be in a race ... a new technique to more efficiently produce the disarmed ... vaccine in large quantities, life-saving inoculations may be available ... as governments worldwide prepare for a predicted pandemic of ...
    Cached Biology News:NIEHS launches website with information for assessing environmental hazards from Hurricane Katrina 2UW scientists report a new method to speed bird flu vaccine production 2UW scientists report a new method to speed bird flu vaccine production 3
    One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
    assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
    One-step, microplate or cuvet, colorimetric, detection range 0.1 mg/dL to 3 mg/dL. Procedure: 10 min....
    Human DCIR/CLEC4A Phycoerythrin MAb (Clone 216110)...
    Biology Products: